Kaushal Kishore

Kaushal Kishore
Kaushal is a pricing transformation lead currently engaged in Merck and based out of Germany. With around 17 plus years of experience in commercial and pricing, Kaushal has been able to drive pricing transformation initiatives in Pharma, Life Sciences and Manufacturing companies. As a seasoned subject matter expert in pricing, Kaushal has successfully set-up industry standard contracting and pricing ‘CoE’ functions. He has been authoring though leadership papers based on his experience and is a professional coach and trainer on the topic. Kaushal has an MBA degree in marketing and has worked internationally in US, UK, Japan, Europe and India
Kaushal is a pricing transformation lead currently engaged in Merck and based out of Germany. With around 17 plus years of experience in commercial and pricing, Kaushal has been able to drive pricing transformation initiatives in Pharma, Life Sciences and Manufacturing companies. As a seasoned subject matter expert in pricing, Kaushal has successfully set-up industry standard contracting and pricing ‘CoE’ functions. He has been authoring though leadership papers based on his experience and is a professional coach and trainer on the topic. Kaushal has an MBA degree in marketing and has worked internationally in US, UK, Japan, Europe and India

Articles: Kaushal Kishore

Cracking the Elusive GtN Code in Pharma Pricing

Global / Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma commercial and pricing organisation which can lead to maturity on the GtN topic, and highlights a successful example that can lead to GtN optimisation not…

Betting the Bottom Dollar on AI in Pricing & Market Access

Global / Merck KGaA’s Marco Rauland and Kaushal Kishore examine how artificial intelligence and machine learning can best be applied in pharmaceutical pricing and market access. Noting the significant uptake of such tools in other aspects of the pharma value chain, Rauland and Kishore speculate how they might come to revolutionise pricing and market access while cautioning…

See more